Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 1,064,861,000, representing an increase of 7.9% compared to RMB 986,691,000 in 2022[4] - Gross profit for the same period was RMB 447,511,000, slightly up from RMB 444,142,000, indicating a stable gross margin[4] - Operating profit decreased significantly to RMB 36,248,000 from RMB 89,293,000, reflecting a decline of 59.6% year-on-year[4] - The net profit attributable to the owners of the company was RMB 24,127,000, down from RMB 54,346,000, marking a decrease of 55.7%[4] - Basic and diluted earnings per share fell to RMB 1.44 from RMB 3.24, a decline of 55.6%[4] - The total reportable segment profit for 2023 was RMB 38,419,000, a decrease of 57.1% from RMB 89,599,000 in 2022[48] - The net profit after tax decreased by approximately 77.24%, from RMB 63,830,000 in the previous year to RMB 14,526,000 this year[92] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 1,415,646,000, compared to RMB 1,448,230,000 in 2022, showing a decrease of 2.2%[5] - The total reportable segment assets increased to RMB 1,763,576,000 in 2023 from RMB 1,716,758,000 in 2022, reflecting a growth of 2.7%[48] - The total reportable segment liabilities rose to RMB 718,342,000 in 2023, compared to RMB 678,732,000 in 2022, an increase of 5.8%[48] - Accounts receivable increased to RMB 197,023,000 in 2023 from RMB 177,007,000 in 2022, representing an increase of about 11.3%[65] - The company reported a total of RMB 149,223,000 in accounts payable for 2023, up from RMB 114,003,000 in 2022, which is an increase of approximately 30.9%[68] - The company's current assets net value increased by approximately RMB 72,038,000 to RMB 554,404,000 compared to RMB 482,366,000 at the end of the previous year[95] Cash Flow and Equity - The company's cash and cash equivalents increased to RMB 372,206,000 from RMB 290,098,000, a rise of 28.3%[5] - The total equity attributable to the owners of the company increased to RMB 908,169,000 from RMB 884,042,000, reflecting a growth of 2.7%[6] - The company’s total receivables, including accounts receivable and notes receivable, amounted to RMB 332,954,000 in 2023, compared to RMB 341,968,000 in 2022, showing a slight decrease of about 2.7%[65] Research and Development - The company reported a total of RMB 46,203,000 in R&D expenses for 2023, up from RMB 28,723,000 in 2022, indicating a significant increase of 60.5%[56] - The group has invested in 35 invention patents and has passed consistency evaluations for 4 products, with several others in progress, including Vitamin B6 tablets awaiting approval[77][78] - New drug applications for the self-developed product Sildenafil Citrate orally disintegrating tablets and the sodium bicarbonate injection are expected to receive production approval in 2024[78] Market and Sales - Revenue from pharmaceutical production and sales was RMB 576,679,000, a decrease of 17% from RMB 694,840,000 in 2022[37] - Revenue from the sale and distribution of pharmaceuticals and health products increased to RMB 488,182,000, up 67% from RMB 291,851,000 in 2022[37] - Medical device sales contributed approximately RMB 210,674,000 to total revenue, compared to RMB 113,600,000 in 2022[37] - The Fuzhou subsidiary, Fuyuan Pharmaceutical, has seen significant growth in its medical device sales and plans to introduce new products in 2024 to ensure steady revenue growth[84] Corporate Governance and Compliance - The consolidated financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and presented in Renminbi (RMB) as the functional currency[12] - The group has adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2023, including HKFRS 17 on insurance contracts[15] - The financial statements for the year have been reviewed and confirmed by the audit committee and external auditors, ensuring compliance with applicable accounting standards[132] Employee and Administrative Expenses - Employee costs for the year ended December 31, 2023, amounted to RMB 44,641,000, compared to RMB 47,107,000 in 2022, reflecting a decrease of approximately 3.3%[17] - The company's administrative expenses were approximately RMB 90,433,000, a decrease of about 3.52% from RMB 93,733,000 in the previous year[90] - The company employed a total of 1,444 employees, a decrease from 1,458 employees in the previous year, with employee costs amounting to approximately RMB 148,985,000[108] Shareholder Information - Major shareholder Haiwang Biological held approximately 94.33% of the company's domestic shares, equating to 1,181,000,000 shares[120] - Haiwang Group, the controlling entity, held approximately 98.52% of the company's shares, totaling 1,233,464,500 shares[120] - The board of directors did not recommend any dividends for the current year, consistent with the previous year[110]
海王英特龙(08329) - 2023 - 年度业绩